Stock listing
LTRN Stock Price, News, Filings & Events — Lantern Pharma Inc.
Selected listing: LTRN · BOATS · USD · US
This page tracks Lantern Pharma Inc.'s LTRN:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following LTRN:BOATS. LTRN:BOATS is the stock-level entry point for investors researching Lantern Pharma Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Lantern Pharma Inc. is a public company traded under the ticker LTRN in the American market. The company has a market capitalization of approximately $35 million. Lantern Pharma focuses on developing targeted cancer therapies using its proprietary technology to improve treatment outcomes for patients.
- Ticker
- LTRN:BOATS
- Asset type
- Stock
- Market cap
- $26.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BOATS
- Currency
- USD
Lantern Pharma Inc. LTRN:BOATS stock context
This page tracks Lantern Pharma Inc.'s LTRN:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following LTRN:BOATS. LTRN:BOATS is the stock-level entry point for investors researching Lantern Pharma Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Lantern Pharma Inc. is a public company traded under the ticker LTRN in the American market. The company has a market capitalization of approximately $35 million. Lantern Pharma focuses on developing targeted cancer therapies using its proprietary technology to improve treatment outcomes for patients.
Latest news from Lantern Pharma Inc.
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scient...
August 3, 2026
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
July 28, 2026
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple So...
July 23, 2026
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biosta...
July 8, 2026
Lantern Pharma Inc. earnings calls
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call
August 14, 2026 · Replay with transcript and chapters
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call
March 30, 2026 · Replay with transcript and chapters
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call
November 13, 2025 · Replay with transcript and chapters
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call
May 15, 2025 · Replay with transcript and chapters
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call
March 27, 2025 · Replay with transcript and chapters
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call
November 7, 2024 · Replay with transcript and chapters
Research Lantern Pharma Inc.
Lantern Pharma Inc. investor report
Review AI stock analysis and investor report context for LTRN:BOATS.
Lantern Pharma Inc. company profile
View the public company page for Lantern Pharma Inc. on 6ix.
Lantern Pharma Inc. news
Read company news and market updates connected to Lantern Pharma Inc..
Lantern Pharma Inc. investor events
Find investor webinars, events, and replay context for Lantern Pharma Inc..